COVID‐19‐associated secondary hemophagocytic lymphohistiocytosis requiring hematopoietic cell transplant

Jacob R. Greenmyer,Kirk D Wyatt,Sam Milanovich,Mira A. Kohorst,Asmaa Ferdjallah
DOI: https://doi.org/10.1002/jha2.456
2022-05-11
eJHaem
Abstract:Coronavirus disease 2019 (COVID-19) infection causes a variety of extrapulmonary complications in pediatric patients. Multisystem inflammatory syndrome and hemophagocytic lymphohistiocytosis (HLH) are related to hypercytokinemia in COVID-19 patients. HLH is a disorder of exaggerated inflammation resulting in a cytokine storm and unrestricted hemophagocytosis. HLH can be primary (familial) or secondary (acquired). Secondary HLH (sHLH) can occur in patients with rheumatologic, oncologic, or infectious diseases. The link between COVID-19 and HLH has been reported in pediatric patients. Here we report a case of a pediatric patient who developed refractory sHLH secondary to COVID-19 infection and required a hematopoietic cell transplant for the cure.
What problem does this paper attempt to address?